Buprenorphine Induction Strategies in the Era of HPSOs

Description

For several years, the predominant substances involved in drug overdose deaths in  the United States have been high-potency synthetic opioids (HPSOs), including fentanyl and its synthetic analogues. Clinicians throughout the country have found that standard buprenorphine induction strategies are no longer sufficient for successfully starting patients on buprenorphine without encountering significant problems with precipitated withdrawal and, in far too many cases, patients returning to opioid use. This presentation will discuss some of the newer high-dose and low-dose strategies for buprenorphine induction that have been utilized and summarized by several members of the American Society of Addiction Medicine (ASAM) in a recently published Clinical Considerations document. Hear the clinical situations in which certain strategies may be more advisable as well as the appropriate clinical setting (inpatient vs. outpatient) for the different strategies.

Learner Objectives

1. Discuss issues raised in patients who present after using HPSOs and other additives/contaminants.
2. Distinguish clinical situations that result in preferences for high- dose or low-dose inductions.
3. Determine when buprenorphine inductions are best performed in a hospital verses outpatient setting.

Presenter

Dr. Stephen M. Taylor, MD, MPH, DFAPA, DFASAM; President-Elect, American Society of Addiction Medicine

Stephen is board-certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine, and for almost 30 years has devoted his professional life to the prevention and treatment of psychiatric and substance use disorders in adolescents and adults.  Dr. Taylor is the Chief Medical Officer of Pathway Healthcare Services, LLC, a company based in Birmingham, AL that currently operates 40 outpatient mental health and addiction treatment offices across 7 states, taking care of over 40,000 patients. For 16 seasons, Dr. Taylor served as the Medical Director of the Player Assistance/Anti-Drug Program of the National Basketball Association (NBA) and the National Basketball Players Association (NBPA). Dr. Taylor is currently the President-Elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM (DFASAM) and a Distinguished Fellow of the American Psychiatric Association (DFAPA). Dr. Taylor is a certified Medical Review Officer (MRO) and serves on the Board of Directors of the Medical Review Officer Certification Council (MROCC). He also serves on the Scientific Advisory Board of the Foundation for Opioid Recovery Efforts. An honors graduate of Harvard College, with a Master of Public Health degree from the Harvard School of Public Health and a medical degree from Howard University College of Medicine, Dr. Taylor completed “Triple Board” residency training in pediatrics, psychiatry, and child and adolescent psychiatry at the Albert Einstein College of Medicine/Bronx Municipal Hospital Center, then completed a fellowship in addiction psychiatry at New York University School of Medicine/Bellevue Hospital Center.

Registration Rates

• $0; free to all attendees
  

Nursing CE

This event is approved for Nursing CE with the California Board of Nursing.

Cancellation

No cancellations. All registrants will have access to a video archive if you are unable to attend in person.